newsfilter
← Latest News
GlobeNewswire·

Surface Oncology to Present New SRF388 Clinical Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

– SRF388 demonstrated clinical activity in multiple solid tumor types withthree confirmed partial responses across NSCLC, RCC and HCC – – Data support continued evaluation of SRF388 in NSCLC, RCC, and first line HCC – – Surface plans to i